Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin for patients with Type 2 diabetes mellitus

References

• Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat. Med.12, 75–80 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn SE. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia46, 319 (2003).
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes37, 667–687 (1988).
   PubMed Web of Science ®Google Scholar
• Muller WA, Faloona GR, Guilar-Parada E, Unger RH. Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med.283, 109–115 (1970).
   PubMed Web of Science ®Google Scholar
• Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab.64, 106–110 (1987).
   PubMed Web of Science ®Google Scholar
• Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N. Engl. J. Med.304, 1518–1524 (1981).
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care30, 162–172 (2007).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2007. Diabetes Care30(Suppl. 1), S4–S41 (2007).
   PubMedGoogle Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion56, 117–126 (1995).
   PubMed Web of Science ®Google Scholar
• Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology140, 1687–1694 (1999).
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia47, 357–366 (2004).
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology132, 2131–2157 (2007).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int. J. Biochem. Cell Biol.38, 831–844 (2006).
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia36, 741–744 (1993).
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in Type 2 diabetes: a parallel-group study. Lancet359, 824–830 (2002).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type II diabetic patients and in healthy subjects. Diabetes44, 1126–1131 (1995).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab.80, 952–957 (1995).
   PubMed Web of Science ®Google Scholar
• Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology136, 3585–3596 (1995).
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese Type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab.88, 220–224 (2003).
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet368, 1696–1705 (2006).
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem.214, 829–835 (1993).
   PubMedGoogle Scholar
• Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci.40, 209–294 (2003).
   PubMed Web of Science ®Google Scholar
• Ryskjaer J, Deacon CF, Carr RD et al. Plasma dipeptidyl peptidase-IV activity in patients with Type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol.155, 485–493 (2006).
   PubMed Web of Science ®Google Scholar
• Marguet D, Baggio L, Kobayashi T et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl Acad. Sci. USA97, 6874–6879 (2000).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes47, 764–769 (1998).
   PubMed Web of Science ®Google Scholar
• Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes50, 1588–1597 (2001).
   PubMed Web of Science ®Google Scholar
• Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of Type 2 diabetes: focus on sitagliptin. Clin. Pharmacol. Ther.81, 761–767 (2007).
   PubMed Web of Science ®Google Scholar
• Bergman A, Mistry GC, Luo WL et al. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm. Drug Dispos.28, 307–313 (2007).
   Google Scholar
• Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care30, 1862–1864 (2007).
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with Type 2 diabetes mellitus. Diabetologia49, 2564–2571 (2006).
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care29, 2632–2637 (2006).
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care29, 2638–2643 (2006).
   PubMed Web of Science ®Google Scholar
• Karasik A, Wu M, Williams-Herman D, Meininger G. Sitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss. Diabetes56(Suppl.1), A139 (2007).
   Google Scholar
• Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with Type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab.9, 194–205 (2007).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia49, 1711–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of Initial Combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with Type 2 diabetes. Diabetes Care30, 1979–1987 (2007).
   PubMed Web of Science ®Google Scholar
• Migoya E, Miller J, Larson M et al. Sitagliptin, a selective dpp-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetes56(Suppl. 1), A74 (2007).
   Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Lunceford JK. Initial combination therapy with sitagliptin and metformin provides effective and durable glycemic control over 1 year in patients with Type 2 diabetes (T2DM): a pivotal Phase III clinical trial Late-breaking abstract (04-LB) (2007). 67th American Diabetes Association Annual Meeting, Chicago, IL, USA 22–26 June (2007).
   Google Scholar
• Stein P, Williams-Herman D, Khatami H et al. Sitagliptin, a selective DPP-4 inhibitor, is well tolerated in patients with Type 2 diabetes: pooled analysis of 5141 patients in clinical trials for up to 2 years. Program and abstracts of the 67th American Diabetes Association (ADA) Annual Meeting, Scientific Sessions, Chicago, IL, USA, 22ndash;26 June (2007) (Abstract 534).
   Google Scholar
• Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of Type 2 diabetes. Diabetes55, 1695–1704 (2006).
   PubMed Web of Science ®Google Scholar